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Dr James M. Douglas (Bellingham, Wash). I congratulate the
authors on their monumental undertaking to develop a comprehen-
sible risk assessment system for the evaluation of the very diverse
and often exceedingly high-risk population of patients undergoing
surgical treatment of endocarditis. In this paper the authors have
convincingly demonstrated the importance of a number of preop-
erative risk factors in this patient cohort that I am certain wewould
all agree are legitimate. However, I am equally intrigued by the
number of questions that may be stimulated by examining this
large data set. To adhere to the time constraints, I will limit these
thoughts to just a few.
Ever sinceWill C. Sealy at Duke proved the improbable by suc-
cessfully performing valve replacement in the patient with active
endocarditis, surgeons have relied on a set of surgical indications
that include congestive heart failure, persistent infection, paravalv-
ular extension, valvular dysfunction, and recurrent emboli. In
essence, surgery has generally been performed in patients in
whommedical therapy has failed. Unfortunately, many of the high-
est risk patients will also die with surgery. Although the scoring
system will confirm what we already know, that is, that the patient
is at high risk, my first question is, can you tell us which patient will
likely die? More specifically, were you able to identify any patient
subgroup for which surgical intervention would be unwise?
My second question is along a similar line. The most important
risk factors for morbidity and mortality that you identified were
primarily functional or physiologic. Using these criteria, you
stated in the paper that the subgroup of patients with the highest
risk scores had operative mortalities that did not exceed 30%.
However, the most vexing patients with endocarditis are those
with serious anatomic challenges, including pseudoaneurysms,
fistulas, and extensive paravalvular abscesses, especially in theThe Journal of Thoracic and Casetting of prosthetic valve endocarditis. Do you believe that the
physiologic parameters trump these anatomic considerations or
would inclusion of these factors in a database better help us to
stratify these patients?
Last, one of your coauthors, Dr Gammie, has previously mined
a database and provided strong support for the use of mitral valve
repair in the treatment of endocarditis. This study likewise attests
to the potential superiority of this approach when feasible. Despite
these data, surgeons may still question the superiority of the tech-
nique itself versus patient selection bias in this heterogeneous pop-
ulation. What are your thoughts on this topic and how do you
suggest we resolve with persistent issue?
Dr Gaca. Who will die? I think that is very interesting. Even
with the highest risk score, our mortality rates, as you correctly
pointed out, did not exceed 30%, so that means every one in this
room is already making these decisions on who will die and who
will not die. That is really a limitation of the database. Only the
people who get surgery are in the database, and I think that we
are doing a very good job. I think we can do better, but that is
the eternal question. That goes into your other question, the lim-
itations of the database. Yes, there are anatomic factors and, no,
they are not included in the database. The big limitation to this
database is that we do not have microbiology data, and one of
the limitations is that we lumped prosthetic valve endocarditis
in with native valve endocarditis. I think that in future data
sets we are going to include the microbiology in the STS data-
base and we are going to try to look at prosthetic endocarditis
alone, because that as you probably can imagine is a different an-
imal. This speaks to the importance of doing these database pa-
pers, because they examine our own clinical practice and allow
us to refine further data sets to answer the questions that you
have raised.
As for mitral repair, you are right. One of our authors has been
a steadfast proponent of mitral valve repair, and indeed mitral
valve repair in this study has actually shown an improved survival.
Obviously not everyone can undergo repair, and are they having
valve repair because their disease is more indolent? That is possi-
ble. Do you we have long-term data? No. I think the next study we
need to do is to link this kind of data to Centers for Medicare and
Medicaid Services data to see what the long-term survival is of
these patients. That is really the next step beyond these STS data
base papers.
DrAnthony Furnary (Portland, Ore). Jeff, you said—I am just
going to read from your abstract—‘‘Interestingly, risk-adjusted
mortality is not improved in recent years, with operative mortality
for 2008 having increased relative to previous years.’’ Did you
present that information?
DrGaca.That is in the paper.We did not present it, but it is true.
Operative mortality from this disease is not getting better, and I
think that has a lot to dowith the fact that endocarditis is a changing
disease. There are a lot more devices being put in people. There is
a rise in staphylococcal infections, so the endocarditis of 5 to 10
years ago is not the same endocarditis that we see this year.
Dr Furnary. Is the risk-adjusted mortality, O/E ratio, getting
worse?
Dr Gaca. It is not improving.
Dr Furnary. It is not getting better.
Dr Gaca. Yes, it is stagnant.rdiovascular Surgery c Volume 141, Number 1 105
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rithms for all valve disease. Would there be a better agreement
or area under the raw curve if you segregated out mitral versus aor-
tic versus tricuspid?
Dr Gaca. Yes, I think so, mainly because people were able to
repair more of the mitral valves. I think the curves for the aortic
and tricuspid valves will be diferent.
Dr Furnary. That is something you would consider?
Dr Gaca. Yes.
Dr Jack Copeland (Tucson, Ariz). Many databases in the past
years have shown a history of smoking as a very powerful predictor
of bad outcome. We have seen it in transplantation and in bridge to
transplantation. Yesterday it was presented as a predictor of bad106 The Journal of Thoracic and Cardiovascular Surgoutcome in lung surgery. Did you include this as part of your anal-
ysis and was it predictive of bad outcome?
Dr Gaca. That is a good question. Smoking was included. It is
in the full model and it was not predictive, but, yes, it is in the
model.
Speaker. Jeff, when you publish your paper in the Journal,
would you be so kind as to publish both the beta coefficients and
the intercept so that we can use these clinically in our centers,
and would you consider publishing separate information for mi-
tral, aortic, and tricuspid?
Dr Gaca. Yes, that information is available. It will be in the
on-line tables owing to the constraints of the Journal, but we
will publish that information.ery c January 2011
